LA-MeO, also known as lysergic acid ethyl-2-methoxyethylamide or as N-ethyl-N-(2-methoxyethyl)lysergamide, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD). It is the O-methyl ether derivative of the LSD metabolite lysergic acid ethyl-2-hydroxyethylamide (LEO).
The drug shows high affinity for the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 4.0nM, 7.1nM, and 7.8nM, respectively). It acts as a potent partial agonist of the serotonin 5-HT2A receptor similarly to LSD, with an of 30.3nM and an of 29.6% (relative to 8.4nM and 22.4% in the case of LSD, respectively).
LA-MeO was first described in the scientific literature by Jason C. Parrish of the lab of David E. Nichols at Purdue University by 2007.
See also Substituted lysergamide Lysergic acid ethyl-2-hydroxyethylamide (LEO) 12-Methoxy-LSD
References
External links LA-MeO - Isomer Design